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The efficacy and side effect profile of antidepressants are
important issues to consider when selecting an antide-
pressant for a patient. Duloxetine is a serotonin (5HT)
and noradrenalin (NE) reuptake inhibitor (SNRI) that
has recently been licensed for the treatment of depres-
sion. This presentation concerns duloxetine’s side effect
profile.
Before considering side effects seen in clinical studies
it is helpful to consider the pharmacokinetic and phar-
macodynamic properties of duloxetine. Duloxetine is
96% protein bound and has an elimination half-life of
about 12 hours. Food has no clinically significant effect
on its absorption. Duloxetine is metabolized by CYP2D6
and CYP1A2. Duloxetine does not inhibit CYP1A2 or
CYP3A4 but it is a moderate inhibitor of cytochrome
CYP2D6. According to published data, duloxetine is a
less potent inhibitor of CYP2D6 than paroxetine, but a
more potent inhibitor of CYP2D6 than sertraline.
Duloxetine has no major active metabolites.
Studies in rats show that following a dose of duloxe-
tine, there are dose dependent increases in both 5HT
and NE in the frontal cortex as measured by microdialy-
sis. Even at lower doses there were measurable increases
in both neurotransmitters. The similarity of the 5HT
and NE curves suggests that effects on both neurotrans-
mitters were present at all doses and rose according to
the dose given.
In clinical trials most side effects seen with duloxetine
are mild and transitory. Side effects that occur in duloxe-
tine-treated patients at a rate of >5% and twice the rate
for placebo are (in descending order of incidence) nausea,
dry mouth, constipation, fatigue, somnolence, increased
sweating and decreased appetite. Nausea, the most com-
mon side effect, is usually mild and resolves within one
week. After the first week of duloxetine treatment, the
percentage of patients reporting new cases of nausea is
similar to patients who receive placebo. Unlike venlafax-
ine, duloxetine is not associated with dose dependent
hypertension. Duloxetine has no clinically relevant effect
on the QT interval. In short-term trials (8–9 week trials)
there is a small but significant amount of weight loss
with Duloxetine. In a 6 month trial the mean weight gain
for Duloxetine 60 mg/day is no different from placebo.
Recent years has seen increasing interest in disconti-
nuation symptoms i.e. symptoms that result from stop-
ping medication. To investigate this phenomenon
several trials had a design that included duloxetine
being stopped abruptly, without taper, after which
patients were followed up for 2 weeks. Discontinuation
symptoms after stopping duloxetine were mild and tran-
sient with the most common symptom being dizziness.
In summary duloxetine appears well tolerated. Its side
effects appear similar to those seen with SSRIs and ven-
lafaxine. Preliminary data suggests that in some areas
duloxetine may have a more favorable side effect profile
than these comparators.
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